CTLA4 and melanoma: More recently, Peters et al. assessed the relationship between the gut microbiome and immunotherapy response (PD-1 and CTLA-4) in melanoma patients (n = 27) and reported that higher microbial community richness was associated with longer PFS (p < 0.05) [8].